Tirzepatide Does Not Cause Nutritional Deficiencies in Large Obesity Trials
Post hoc analysis of four SURMOUNT trials found tirzepatide did not worsen nutritional status in people with obesity, despite reduced appetite and food intake.
Quick Facts
What This Study Found
Tirzepatide treatment across the SURMOUNT-1-4 trials was not associated with worsening nutritional status despite appetite and dietary intake reduction.
Key Numbers
How They Did This
Post hoc descriptive analysis of nutritional data from four randomized, placebo-controlled, phase 3 trials (SURMOUNT-1 through SURMOUNT-4).
Why This Research Matters
A major concern with potent appetite suppressants is that patients may not get adequate nutrition. This data is reassuring for the millions using or considering tirzepatide.
The Bigger Picture
As obesity medications that dramatically reduce appetite become widespread, monitoring nutritional adequacy is essential to ensure weight loss does not come at the cost of malnutrition.
What This Study Doesn't Tell Us
Post hoc analysis — not designed primarily to assess nutritional outcomes; descriptive statistics limit causal conclusions; trial populations may not represent all real-world users.
Questions This Raises
- ?Should nutritional monitoring be standard practice for patients on long-term tirzepatide?
- ?Do specific subgroups (elderly, post-bariatric surgery) face higher nutritional risk?
Trust & Context
- Key Stat:
- 4,726 participants Across four phase 3 trials, no worsening of nutritional status observed
- Evidence Grade:
- Post hoc analysis of RCT data — leverages strong trial infrastructure but was not pre-specified, limiting the strength of conclusions.
- Study Age:
- Published 2026. Analyzes data from the landmark SURMOUNT trial program.
- Original Title:
- Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials.
- Published In:
- Obesity pillars, 17, 100248 (2026)
- Authors:
- Almandoz, Jaime P(4), Pickett-Blakely, Octavia, Tewksbury, Colleen, Stefanski, Adam, Gonsahn-Bollie, Sylvia, Dimitriadis, Georgios K, Murro, Ada Leticia, Cao, Dachuang, Meng, Qier, Neff, Lisa M
- Database ID:
- RPEP-14748
Evidence Hierarchy
Frequently Asked Questions
Can tirzepatide cause you to become malnourished?
This analysis of over 4,700 trial participants found no evidence of worsening nutritional status with tirzepatide, despite the medication's appetite-reducing effects.
Should I take vitamins while on tirzepatide?
While this study is reassuring, maintaining a balanced diet and discussing supplementation with your doctor is always advisable during any weight loss program.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14748APA
Almandoz, Jaime P; Pickett-Blakely, Octavia; Tewksbury, Colleen; Stefanski, Adam; Gonsahn-Bollie, Sylvia; Dimitriadis, Georgios K; Murro, Ada Leticia; Cao, Dachuang; Meng, Qier; Neff, Lisa M. (2026). Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials.. Obesity pillars, 17, 100248. https://doi.org/10.1016/j.obpill.2026.100248
MLA
Almandoz, Jaime P, et al. "Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials.." Obesity pillars, 2026. https://doi.org/10.1016/j.obpill.2026.100248
RethinkPeptides
RethinkPeptides Research Database. "Nutritional status with tirzepatide in obesity: A post hoc a..." RPEP-14748. Retrieved from https://rethinkpeptides.com/research/almandoz-2026-nutritional-status-with-tirzepatide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.